Emotional functions in short-term vs. long-term L-Dopa therapy in parkinsonism
β Scribed by Michael B. Maskin; Manuel Riklan; David Chabot
- Publisher
- John Wiley and Sons
- Year
- 1973
- Tongue
- English
- Weight
- 223 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0021-9762
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
YTOTOXIC AGENTS have been used for C more than a decade in therapy of rheumatoid However, therapy with these agents has not been widely adopted. It has been restricted, in general, to short intensive courses for acutely ill, hospitalized patients as utilized in cancer chemotherapy. We have used Cyc
Deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) or the globus pallidus pars interior (GPi) represents one of the major therapeutic breakthroughs in the treatment of Parkinson's disease (PD). Despite the complexity of the procedure, the need to integrate a team of neurologists, n
Clonogenic capacity of bone marrow progenitors and stromal layers established from bone marrow of 12 patients with CML and 13 healthy controls were evaluated. The initial BFU-E and CFU-GM contents were slightly higher in the CML patients (p > 0.05) in contrast to CFU-GEMM. CFU-GEMM was lower in the
This double-blind study evaluates the ecacy and tolerability of Β―uoxetine and citalopram in the acute and long-term treatment of panic disorder in 42 patients meeting DSM-IV criteria for panic disorder with or without agoraphobia. Fluoxetine and citalopram showed similar ecacy in the treatment of pa